Rachel Niknam, MD
Ophthalmology · Philadelphia, PANPI 1649215245
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $97,437 of the $142,259 with a category attached, or 68.5%. AbbVie accounts for 77.7% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2022 at $54,128 and has fallen 76.8% since, to $12,534 in 2025. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 403 payments — averaging $353.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$111K
- Aerie Pharmaceuticals, Inc.$15K
- Glaukos Corporation$11K
- Alcon$2K
- Sight Sciences, Inc.$629
- Novartis$458
- plus $3K from 20 others
What the payments were for
- Consulting fees$18,12013%
- Speaking & faculty fees$97,43768%
- Travel & lodging$16,20711%
- Food & beverage$10,4507%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 194 | $110,602 |
| Aerie Pharmaceuticals, Inc. | 27 | $14,997 |
| Glaukos Corporation | 9 | $10,638 |
| Alcon | 46 | $1,826 |
| Sight Sciences, Inc. | 5 | $629 |
| Novartis | 18 | $458 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $442 |
| NEW World Medical,inc. | 11 | $421 |
| Rxsight Inc | 5 | $379 |
| Tarsus Pharmaceuticals, Inc. | 10 | $347 |
| Bausch & Lomb Americas Inc. | 16 | $314 |
| Sun Pharmaceutical Industries Inc. | 17 | $300 |
| Oyster Point Pharma, Inc. | 7 | $192 |
| Eyevance Pharmaceuticals LLC | 5 | $160 |
| Mallinckrodt Hospital Products Inc. | 6 | $132 |
| Harrow Eye, LLC | 4 | $90 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $69 |
| Biotissue Holdings Inc. | 4 | $63 |
| Amgen | 2 | $42 |
| Ocular Therapeutix, Inc. | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 2 | $35 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Dompe US, Inc. | 1 | $22 |
| Akorn, Inc. | 1 | $18 |
| Eyepoint US, Inc. | 1 | $14 |
| Lumibird Medical Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$92,032
- Rhopressa$14,621
- Rocklatan$14,621
- LUMIGAN$9,568
- COMBIGAN$6,333
- Travoprost Intraocular Implant - iDose$5,869
- ALPHAGAN P$1,000
- OMNI$500
- Tecnis IOL$357
- RXSIGHT CONTACT LENS$341
- RXSIGHT INJECTOR CARTRIDGE$341
- RXSIGHT INJECTOR HANDPIECE$341
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$341
- LIGHT ADJUSTABLE LENS (LAL)$341
- Kahook Dual Blade$290
- Clearpath$290
- Ahmed Glaucoma Valve$290
- Streamline$290
- XEN GLAUCOMA TREATMENT SYSTEM$254
- Via360$170
How this compares
$142,259 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 340 | $208,316 |
| RestasisCyclosporine | 80 | $96,736 |
| RhopressaNetarsudil Mesylate | 119 | $71,178 |
| CombiganBrimonidine Tartrate/Timolol | 123 | $59,004 |
| RocklatanNetarsudil Mesylat/Latanoprost | 51 | $30,420 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 96 | $21,081 |
| XdemvyLotilaner | 11 | $20,818 |
| Prednisolone Acetate | 341 | $18,318 |
| Brinzolamide | 80 | $16,253 |
| Alphagan PBrimonidine Tartrate | 44 | $15,275 |
| Cyclosporine | 21 | $11,721 |
| Latanoprost | 767 | $10,962 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 30 | $10,672 |
| MieboPerfluorohexyloctane/Pf | 14 | $10,559 |
| Brimonidine Tartrate | 144 | $10,428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $110,602 | $379,331587 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $14,997 | $101,598170 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $347 | $20,81811 claims |
| AlconSimbrinza | $1,826 | $10,67230 claims |
| Bausch & Lomb Americas Inc.Miebo | $314 | $10,55914 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $69 | $5,43937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Philadelphia
- Julia HallerPhiladelphia$1.5M
- Beeran MeghparaPhiladelphia$496K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
- Anton KolomeyerPhiladelphia$355K
- Durga BorkarPhiladelphia$150K
- Joseph MarkoffPhiladelphia$130K
- Leslie KatzPhiladelphia$105K
- Zeba SyedPhiladelphia$99K
- Cesar BricenoPhiladelphia$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.